Kuria Therapeutics, Inc
Publicly observedLittle Rock, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Little Rock | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Kuria Therapeutics, Inc | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | F7M7TD9GDA55 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant1 Sept 2026Publicly observed
NIH SBIR/STTR award: Testing of SCO-116, an NRF2 activator for Fuchs' Dystrophy, in cultured human corneas
USD 306,805.00 · National Eye Institute · Source: NIH RePORTER (opens in a new tab)
- Grant30 Sept 2025Publicly observed
NIH SBIR/STTR award: IND-enabling studies of KTX-1161, a novel NRF2 activator for corneal endothelial disease
USD 399,865.00 · National Eye Institute · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.